Treatment Clinical Trials for Non-Melanoma Skin Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for non-melanoma skin cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 151-175 of 180

  • IRX-2 Regimen, Cyclophosphamide, and Durvalumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    This phase Ib trial studies the side effects and best dose of the IRX-2 regimen when given together with cyclophosphamide and durvalumab in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or has spread to other places in the body (metastatic). Many cancers in humans, including head and neck cancer, are associated with defects in the immune system. IRX-2 is a mixture of substances made by human cells stimulated in a laboratory to make these substances (proteins) that can “turn on” the immune system. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known if the IRX-2 regimen, cyclophosphamide, and durvalumab will work better in treating patients with head and neck squamous cell carcinoma.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Fluorouracil with or without Imiquimod for the Treatment of Squamous Cell Carcinoma of the Lower Extremities

    This phase I trial studies the side effects of fluorouracil with or without imiquimod in treating patients with squamous cell carcinoma of the lower extremities. Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Imiquimod may activate the immune system by stimulating the immune response which recruits pathogen fighting cells. Giving fluorouracil together with imiquimod may eliminate the need for surgery by significantly shrinking and / or eliminating the tumor, thereby preventing surgical complications and improving post-treatment outcomes in patients with squamous cell carcinoma of the lower extremities.
    Location: UPMC-Saint Margaret, Pittsburgh, Pennsylvania

  • Cobimetinib and Atezolizumab in Treating Participants with Advanced or Refractory Rare Tumors

    This phase II trial studies how well cobimetinib and atezolizumab work in treating participants with rare tumors that have spread to other places in the body (advanced) or that does not respond to treatment (refractory). Cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cobimetinib and atezolizumab may work better in treating participants with advanced or refractory rare tumors.
    Location: M D Anderson Cancer Center, Houston, Texas

  • CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients with Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

    This phase I / II trial studies the best dose and side effects of recombinant human EGF-rP64K / montanide ISA 51 vaccine (CIMAvax) and nivolumab or pembrolizumab and to see how well they work in treating patients with non-small cell lung cancer or squamous head and neck cancer that has spread to other places in the body. Vaccine therapy, such as CIMAvax vaccine, may help slow down and stop tumor growth. Immunotherapy with monoclonal antibodies, such as nivolumab and pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving CIMAvax vaccine together with nivolumab or pembrolizumab may work better in treating patients with non-small cell lung cancer or squamous head and neck cancer.
    Location: Roswell Park Cancer Institute, Buffalo, New York

  • Nimotuzumab and Nivolumab in Treating Patients with Advanced Non-small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

    This phase I / II trial studies the best dose and side effects of nimotuzumab when giving together with nivolumab and to see how well they work in treating patients with non-small cell lung cancer or squamous cell head and neck cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Monoclonal antibodies, such as nimotuzumab, may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nimotuzumab and nivolumab may work better in treating patients with non-small cell lung cancer.
    Location: Roswell Park Cancer Institute, Buffalo, New York

  • Pembrolizumab in Treating Patients with Rare Tumors That Cannot Be Removed by Surgery or are Metastatic

    This phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body (metastatic). Monoclonal antibodies, such as pembrolizumab, may block specific proteins found on white blood cells which may strengthen the immune system and control tumor growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Cytotoxic T Lymphocytes in Treating Patients with Malignancies with BK and / or JC Virus

    This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and / or JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and / or JC virus.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    The purpose of this study is to evaluate if the addition of GSK3359609 to pembrolizumab in combination with 5FU-platinum based chemotherapy improves the efficacy of the pembrolizumab combination with 5FU-platinum based chemotherapy in participants with recurrent or metastatic (R / M) head and neck squamous cell carcinoma (HNSCC). This randomized, double-blinded, Phase II / III study will compare the combination of GSK3359609 with pembrolizumab and 5FU-platinum chemotherapy to placebo in combination with pembrolizumab and 5FU-platinum chemotherapy in participants with recurrent or metastatic HNSCC of the oral cavity, oropharynx, hypopharynx or larynx. Approximately 640 participants will be enrolled in the study.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1

    This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with advanced unresectable and / or metastatic Merkel Cell Carcinoma that have progressed on a previous therapy with an anti-PD-(L)1 antibody
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Study of PDS0101 and Pembrolizumab Combination I / O in Subjects With HPV16 + Recurrent and / or Metastatic HNSCC

    VERSATILE-002 is a Phase 2, open-label, multicenter study of the efficacy and safety of PDS0101 administered in combination with pembrolizumab in the first line treatment of adults with HPV16 and PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
    Location: 4 locations

  • Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen

    In Phase IIa, dose-escalation study to determine the optimum tolerated dose and a recommended Phase IIb (RPIIb) dose in combination with pembrolizumab in subjects with recurrent or metastatic squamous cell carcinoma of the head and neck who have failed platinum or a platinum containing regimen. In Phase IIb, randomized control study between NC-6004 in combination with pembrolizumab versus pembrolizumab alone in the same subject population as Part 1 at the RPIIb dose identified in PIIa.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

    The primary purpose of this study is to see if Sym024 is safe and tolerable as monotherapy and in combination with Sym021 in patients with solid tumor malignancies.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

    This is a randomized, double-blind, multicenter, global Phase 3 study to assess the efficacy and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in patients with recurrent or metastatic head and neck cancer.
    Location: University of California San Francisco, San Francisco, California

  • Phase I / II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap" / PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

    Background: Combination immunotherapy techniques are being explored to improve responses and enhance benefits in people with cancer. Researchers want to see if this type of treatment can help people with advanced solid tumors. Objective: To find a safe dose of SX-682 in combined treatment with Bintrafusp alfa and BN-CV301 vaccines and to see if this treatment will cause tumors to shrink. Eligibility: Adults age 18 and older with metastatic cancer may be eligible for the first part of the trial. Adults age 18 and older with metastatic triple negative breast cancer or p16 negative head and neck squamous cell cancer, and who are not candidates for curative surgery may be eligible for the second part of the trial. Design: Participants will be screened under a separate protocol. Participants may have tumor biopsies. They will have physical exams. Their symptoms and medicines will be reviewed. They will have blood tests. They will have electrocardiograms to evaluate their heart. Participants will have imaging scans of the chest, abdomen, and pelvis. They may have a procedure where a small tube with a tiny video camera is put into the nose to look at the throat if they have head and neck cancers. Participants will get bintrafusp alfa through an intravenous catheter. For this, a small tube is put into an arm vein. They will get BN-CV301 vaccines as injections in the arm or thigh. They will take SX-682 by mouth twice a day. They will take the study drugs up to 2 years. They will keep a medicine diary. Participants will have study visits every 2 weeks. They will have 1 or 2 follow-up visits within 30 days after they stop treatment. Then they will be monitored by phone or email for 2 years.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • A Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy

    The primary objective of the study is to demonstrate superior efficacy of Debio 1143 vs placebo when added to chemoradiotherapy (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
    Location: 3 locations

  • Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations

    Preclinical data and limited clinical evidence suggest that Head and Neck Squameous Cell Carcinoma tumors harboring certain mutations may respond well to PI3K / mTOR inhibition (phosphatidylinositol-3-kinase / mammalian target of rapamycin inhibition). The current study enrolls patients with refractory and / or metastatic Head and Neck Squameous Cell Carcinoma based on the mutational status of their disease to assess the response to treatment with bimiralisib, an orally available pan-PI3K / mTOR inhibitor (phosphatidylinositol-3-kinase / mammalian target of rapamycin inhibitor).
    Location: See Clinical Trials.gov

  • An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

    The purpose of the dose escalation part of this study is to determine the feasibility of using the combination of copanlisib and nivolumab in subjects with advanced solid tumors, and to determine the maximum tolerated dose of copanlisib in combination with nivolumab. The maximum tolerated dose will then be used in Phase 2 (dose expansion) of the study.
    Location: 5 locations

  • Open-Label Dose Escalation Trial to Evaluate Dose Limiting Toxicity and Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in BCC

    This is a Phase I study in participants with superficial or nodular Basal Cell Carcinoma (BCC), designed to assess dose limiting toxicities and maximum tolerated dose, efficacy, safety, and tolerability of dissolvable, tip-loaded, microneedle arrays containing doxorubicin (D-MNA). Doxorubicin is a cytotoxic anthracycline antibiotic and is currently approved for the treatment of a broad range of cancers, including but not limited to: breast, bladder, gastric, and ovarian cancers; small cell lung cancer; acute lymphoblastic leukemia; and acute myelo blastic leukemia. SkinJect, Inc. has developed a novel delivery system in the form of a tip-loaded dissolvable microneedle array (MNA) which will allow for topical delivery of doxorubicin directly to the lesion at concentrations that are far below standard systemic dosing, thereby reducing the adverse events associated with systemic delivery. The primary objective of this investigation is to establish the highest safe and tolerable dose of single applications of D-MNA, one application per week for three weeks in placebo, 25 µg, 50 µg, 100 µg, and 200 µg dose groups in participants with BCC.
    Location: See Clinical Trials.gov

  • Basket Study to Evaluate the Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Advanced and / or Metastatic Solid Tumors

    This is an open-label, multicenter, basket trial Phase II study to evaluate the antitumor activity of RO6874281 in combination with atezolizumab in participants with advanced and / or metastatic solid tumors. Currently the focus is on patients with Head and Neck, oesophageal and cervical cancers with confirmed squamous cell carcinoma histology type.
    Location: See Clinical Trials.gov

  • X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma

    In this Phase I trial for subjects with advanced head & neck cancer, breast cancer, soft tissue sarcoma or melanoma all subjects will receive open label X-PACT treatment as a intra-tumoral injection. The primary objective will be to establish the safety of X-PACT when dosed with 5 intra-tumoral injections of the combination product (the phosphor device and methoxsalen sterile solution and subsequently exposing the tumor to X-ray energy) over a period of 6 weeks (on day D1, D3 and D5 of Week 1, on D1 of Week 2, and a booster on D1 of Week 6). After the week 8 tumor assessment subjects demonstrating stable disease, partial response or unconfirmed progression assessed by iRecist, will be eligible to receive two additional booster treatments 4-6 weeks apart. Treatment will be considered safe provided ≤ 2 out of 12 patients experience a dose-limiting toxicity (DLT) during the 6 weeks after the first intra-tumoral injection.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin

    This is a Phase 1 open-label, multi-center, dose-escalation study to evaluate the safety, PK, anti-tumor activity, and pharmacodynamic effects of SL-172154 administered by intratumoral injection in subjects with cutaneous squamous cell carcinoma (CSCC) or squamous cell carcinoma of the head and neck (SCCHN).
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Testing the Addition of an Anti-cancer drug, BAY1895344, with Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

    This phase I trial evaluates the side effects and best dose of BAY1895344 and radiation therapy when given together with pembrolizumab and to see their effect in treating patients with head and neck squamous cell cancer that has come back (recurrent) and cannot be removed by surgery (unresectable). BAY1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving BAY1895344 and radiation therapy in combination with pembrolizumab may shrink or stabilize head and neck squamous cell cancer for longer than the usual approach alone.
    Location: Location information is not yet available.

  • Cemiplimab before and after Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

    This phase I trial studies how well cemiplimab before and after surgery works in treating patients with high risk cutaneous squamous cell cancer. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cemiplimab before surgery may improve risk of the cancer returning in patients with high risk cutaneous squamous cell cancer.
    Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia

  • Personalized Vaccine (PANDA-VAC) and Pembrolizumab for the Treatment of Squamous Cell Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

    This phase I trial studies the side effects of a personalized vaccine (PANDA-VAC) when giving together with pembrolizumab in treating patients with squamous cell non-small cell lung cancer or squamous cell head and neck cancer. Abnormal cells, such as cancer cells, have special substances on their surface (called neoantigens) that are not found in normal cells. The personalized vaccine is a mix of neoantigens that are specific to the person's cancer. Vaccines work to boost the immune response in fighting abnormal cells. Immune cells can recognize these neoantigen substances and destroy the abnormal cells that carry them. After this, the immune system has a “memory” that helps it respond to those substances in the future. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving PANDA-VAC in combination with pembrolizumab may help strengthen the way the immune system responds to squamous cell non-small cell lung cancer and squamous cell head and neck cancer.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa Associated Unresectable, Locally Advanced, or Metastatic Squamous Cell Skin Cancer

    This early phase I trial studies the side effects and how well rigosertib works in treating patients with recessive dystrophic epidermolysis bullosa and squamous cell skin cancer that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced), or has spread to other places in the body (metastatic). Rigosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania